Loading patent…
AssigneeUnison Pharmaceuticals Pvt. Ltd.
InventorsBalvir SINGH, Pushpendra SINGH, Divyesh KATHROTIA, Tejas PATEL
Estimating the term…
The present invention relates to a stable pharmaceutical composition comprising combination of a therapeutically effective amount of Sodium-glucose co-transporter-2 (SGLT2) inhibitor and a therapeutically effective amount of Dipeptidyl peptidase-4 (DPP4) inhibitor for reducing blood glucose level in patients with diabetes. The present invention specifically relates to a stable pharmaceutical composition comprising Dapagliflozin or a pharmaceutically acceptable salts or solvates thereof, and Linagliptin or a pharmaceutically acceptable salts or solvates thereof in presence of one or more pharmaceutically acceptable excipients. Moreover, the present invention relates to a stable pharmaceutical composition comprising Dapagliflozin. Linagliptin and one or more pharmaceutically acceptable excipients with reduced degradation impurities.
A stable pharmaceutical composition comprising a combination of Linagliptin or pharmaceutically acceptable salt or solvate thereof with Dapagliflozin or pharmaceutically acceptable salt or solvate thereof and at least one pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.